Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Submitted by
admin
on February 24, 2025 - 11:15am
Source:
Benzinga
News Tags:
Entrada Therapeutics
ENTR-601-44
DMD
Duchenne Muscular Dystrophy
FDA
Headline:
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
snippet:
FDA lifted the clinical hold on Entrada's ENTR-601-44, allowing the Phase 1b ELEVATE-44-102 study for Duchenne muscular dystrophy to proceed
The trial will assess safety, target engagement and dosing in 32 ambulatory and non-ambulatory patients amenable to exon 44 skipping.
Do Not Allow Advertisers to Use My Personal information
